Medicilon 美迪西
8 significant filings since 31 May 2026: 1 on litigation, 2 on change of interest and 2 on major holder selling, and 3 other kinds. The latest, on 22 Sep 2026: 美迪西：关于股东权益变动触及1%刻度的提示性公告. On 20 Jul 2026 the company said it expects net profit for the period ending 30 Jun 2026 to rise by 425.62% to 588.43% from the same period a year earlier.
自 31 May 2026 起有 8 份重大公告：litigation 1 份、change of interest 2 份、major holder selling 2 份，另有 3 类。最新一份（22 Sep 2026）：美迪西：关于股东权益变动触及1%刻度的提示性公告。20 Jul 2026 公司预告截至 30 Jun 2026 的净利润较上年同期上升 425.62% 至 588.43%。
Price History 价格走势
22 trading days 个交易日 · High 最高 ¥117.08 · Low 最低 ¥89.34| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥141亿 | ¥73亿 | 15th highest of 54 · 54 家中第 15 高 | |
| Trailing P/E 市盈率 | — | 103.6x | No value 无数据 | |
| P/B 市净率 | 7.1x | 3.4x | 7th highest of 54 · 54 家中第 7 高 | |
| Revenue Growth 营收增速 | 40.9% | 4.0% | 4th highest of 54 · 54 家中第 4 高 | |
| Profit Growth 净利增速 | 500.1% | 3.3% | 7th highest of 54 · 54 家中第 7 高 | |
| Gross Margin 毛利率 | 31.6% | 33.3% | 24th lowest of 54 · 54 家中第 24 低 | |
| Net Margin 净利率 | 6.8% | 5.8% | 25th highest of 54 · 54 家中第 25 高 | |
| Return on Equity 净资产收益率 | 2.6% | 2.0% | 23rd highest of 54 · 54 家中第 23 高 | |
| Debt to Assets 资产负债率 | 30.5% | 28.7% | 25th highest of 54 · 54 家中第 25 高 | |
| Grade Score 评级得分 | 64 | 52 | 12th highest of 53 · 53 家中第 12 高 |
Statement figures are for the period to 30 Jun 2026, filed by 54 of 54 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，54 家同业中 54 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Wuxi Apptec 药明康德 | ¥4,910亿 | 22.7x | 5.8x | 38.9% | 38.5% | 13.2% | B |
| Pharmaron Beijing 康龙化成 | ¥792亿 | 46.3x | 4.8x | 17.9% | 9.4% | 4.6% | C |
| Aier Eye Hospital Group 爱尔眼科 | ¥731亿 | 28.7x | 3.2x | 3.8% | 12.9% | 6.0% | C |
| Asymchem Laboratories 凯莱英 | ¥653亿 | 63.1x | 3.7x | 13.1% | 14.3% | 2.9% | C |
| Biocytogen 百奥赛图 | ¥568亿 | 155.2x | 23.5x | 51.6% | 25.6% | 10.5% | B |
| Hangzhou Tigermed Consulting 泰格医药 | ¥489亿 | 535.1x | 2.5x | 14.1% | -5.0% | -2.0% | D |
| Joinn 昭衍新药 | ¥340亿 | 34.6x | 3.8x | 5.3% | 106.2% | 8.6% | B |
| Haoyuan Chemexpress 皓元医药 | ¥214亿 | 82.7x | 6.7x | 25.7% | 9.8% | 5.3% | C |
| BGI Genomics 华大基因 | ¥187亿 | — | 2.2x | 9.6% | 2.7% | 0.6% | D |
| Hitgen 成都先导 | ¥175亿 | 124.9x | 11.5x | 52.4% | 23.0% | 5.2% | B |
| Meinian Onehealth Healthcare Holdings 美年健康 | ¥173亿 | 53.2x | 2.2x | -6.4% | -5.0% | -2.2% | E |
| Topchoice Medical 通策医疗 | ¥148亿 | 24.0x | 3.6x | 4.1% | 32.8% | 9.5% | C |
| Jiuzhou Pharma 九洲药业 | ¥145亿 | 24.5x | 1.6x | -10.3% | 14.8% | 4.3% | C |
| Gempharmatech 药康生物 | ¥144亿 | 78.8x | 6.3x | 22.6% | 24.1% | 4.8% | B |
| Medicilon 美迪西 | ¥141亿 | — | 7.1x | 40.9% | 6.8% | 2.6% | C |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。